Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advanced gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial
机构：[1]Tianjin Med Univ, Tianjin, Peoples R China[2]Shanxi Prov Canc Hosp, Taiyuan, Shanxi, Peoples R China[3]Hebei Med Univ 4 Hosp, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院
第一作者机构：[1]Tianjin Med Univ, Tianjin, Peoples R China
推荐引用方式(GB/T 7714)：
Yan Y.,Lu L.,Wang X.,et al.Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advanced gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial[J].ANNALS OF ONCOLOGY.2020,31:S111-S111.doi:10.1016/j.annonc.2020.04.149.
APA：
Yan, Y.,Lu, L.,Wang, X.,Wang, D.,Huang, Q....&Fu, W..(2020).Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advanced gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial.ANNALS OF ONCOLOGY,31,
MLA：
Yan, Y.,et al."Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advanced gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial".ANNALS OF ONCOLOGY 31.(2020):S111-S111
医学